Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Phone858-750-4700
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees39
Next Earnings Date11/7/2019 (Estimated)
OptionableNot Optionable
Synthorx (NASDAQ:THOR) Frequently Asked Questions
What is Synthorx's stock symbol?
Synthorx trades on the NASDAQ under the ticker symbol "THOR."
How were Synthorx's earnings last quarter?
Synthorx Inc (NASDAQ:THOR) released its earnings results on Thursday, August, 1st. The medical instruments supplier reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.36) by $0.03. View Synthorx's Earnings History.
When is Synthorx's next earnings date?
What price target have analysts set for THOR?
4 brokers have issued 1-year target prices for Synthorx's stock. Their predictions range from $21.00 to $30.00. On average, they anticipate Synthorx's share price to reach $25.50 in the next year. This suggests a possible upside of 101.9% from the stock's current price. View Analyst Price Targets for Synthorx.
What is the consensus analysts' recommendation for Synthorx?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthorx in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synthorx.
What are Wall Street analysts saying about Synthorx stock?
Here are some recent quotes from research analysts about Synthorx stock:
- 1. According to Zacks Investment Research, "Synthorx Inc. is a biopharmaceutical company which focuses on cancer and autoimmune disorders. The company's product pipeline consists of THOR-707, IL-2 autoimmune synthorin, IL-10 synthorin and IL-15 synthorin which are in clinical stage. Synthorx Inc. is based in La Jolla, CA. " (10/2/2019)
- 2. HC Wainwright analysts commented, "Our 12-month, $30 price target on shares of Synthorx is based on a 12-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.5, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2029. We assign a 9% POS for THOR-707, which we anticipate could be developed in NSCLC, RCC, melanoma, and urothelial cancer. These indications together represent about 95% of our target with NSCLC being the biggest driver of valuation, elaborated upon subsequently." (5/1/2019)
Has Synthorx been receiving favorable news coverage?
Media coverage about THOR stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Synthorx earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned press coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Synthorx.
Who are some of Synthorx's key competitors?
Some companies that are related to Synthorx include Aimmune Therapeutics (AIMT), Alder Biopharmaceuticals (ALDR), Insmed (INSM), Nabriva Therapeutics (NBRV), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), Opko Health (OPK), Eidos Therapeutics (EIDX), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), BELLUS Health (BLUSF), Zymeworks (ZYME) and Turning Point Therapeutics (TPTX).
What other stocks do shareholders of Synthorx own?
Who are Synthorx's key executives?
Synthorx's management team includes the folowing people:
- Dr. Laura K. Shawver, CEO, Pres & Director (Age 61)
- Dr. Floyd E. Romesberg, Scientific Founder & Director (Age 53)
- Dr. Marcos Milla Ph.D., Chief Scientific Officer (Age 56)
- Dr. Joseph Leveque, Chief Medical Officer (Age 58)
- Terry L. Button, VP & Director
When did Synthorx IPO?
(THOR) raised $100 million in an initial public offering (IPO) on Friday, December 7th 2018. The company issued 9,100,000 shares at $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.
How do I buy shares of Synthorx?
Shares of THOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Synthorx's stock price today?
One share of THOR stock can currently be purchased for approximately $12.63.
How big of a company is Synthorx?
Synthorx has a market capitalization of $407.57 million. The medical instruments supplier earns $-56,610,000.00 in net income (profit) each year or ($6.59) on an earnings per share basis. Synthorx employs 39 workers across the globe.View Additional Information About Synthorx.
What is Synthorx's official website?
How can I contact Synthorx?
Synthorx's mailing address is 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037. The medical instruments supplier can be reached via phone at 858-750-4700 or via email at [email protected]
MarketBeat Community Rating for Synthorx (NASDAQ THOR)
MarketBeat's community ratings are surveys of what our community members think about Synthorx and other stocks. Vote "Outperform" if you believe THOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe THOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
